Johnson Financial Group Inc (Wisconsin)’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-6,988
Closed -$121K – 1043
2025
Q3
$121K Hold
6,988
– – ﹤0.01% 425
2025
Q2
$65.5K Buy
6,988
+1,388
+25% +$11.4K ﹤0.01% 430
2025
Q1
$39.8K Buy
+5,600
New +$56.6K ﹤0.01% 653
2024
Q3
– Sell
-3,856
Closed -$86.3K – 1006
2024
Q2
$86.3K Buy
+3,856
New +$91.8K ﹤0.01% 393

Other funds holding NTLA

Johnson Financial Group Inc (Wisconsin)'s NTLA Position: Q4 2025 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 6,988 shares — an estimated $121K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in NTLA in Q2 2024 and held it in 4 quarters. The position peaked at $121K in Q3 2025. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Johnson Financial Group Inc (Wisconsin) reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Johnson Financial Group Inc (Wisconsin) sold 6,988 Intellia Therapeutics shares in Q4 2025, an estimated $121K.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in Intellia Therapeutics in Q2 2024 and held it in 4 quarters.
  • Johnson Financial Group Inc (Wisconsin)'s Intellia Therapeutics position peaked at $121K in Q3 2025.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q4 2025, filed 12 Feb 2026.